Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
22nd Century ( (XXII) ) has issued an update.
On November 4, 2025, 22nd Century Group, Inc. entered into a Sales Agreement with Needham & Company, LLC to issue and sell shares of common stock up to $25 million, intending to use the proceeds for corporate purposes including the expansion of its VLN® products. The company also reported its third quarter 2025 financial results, highlighting a significant balance sheet improvement with no outstanding debt and a $9.5 million insurance settlement. The company is expanding its market reach with VLN® products, increasing store counts, and securing new distribution agreements, positioning itself for future growth in the tobacco industry.
The most recent analyst rating on (XXII) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on 22nd Century stock, see the XXII Stock Forecast page.
Spark’s Take on XXII Stock
According to Spark, TipRanks’ AI Analyst, XXII is a Underperform.
22nd Century’s stock score is primarily impacted by its poor financial performance and weak technical indicators. The company’s financial instability, marked by declining revenues and high leverage, is a significant concern. The technical analysis further reflects a bearish outlook, with the stock trading below key moving averages. Valuation metrics offer no support, as the P/E ratio is zero and there is no dividend yield. While the strategic shift to high-margin products is a positive development, the delay in profitability and potential cash flow issues remain significant risks.
To see Spark’s full report on XXII stock, click here.
More about 22nd Century
22nd Century Group, Inc. is a tobacco products company that focuses on reducing the harms of smoking through its VLN® reduced nicotine content tobacco cigarettes. The company is a leader in the Tobacco Harm Reduction Movement and aims to align with the FDA’s Low Nicotine Mandate.
Average Trading Volume: 1,517,317
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.86M
For a thorough assessment of XXII stock, go to TipRanks’ Stock Analysis page.